Menu
← Oncology Approval Tracker
FDA DECISION ·
Carvykti
ciltacabtagene autoleucel · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after at least one prior line that included a proteasome inhibitor and immunomodulatory agent, and with lenalidomide-refractory disease.
LAMPGEN ANALYSIS
Why it matters
The BCMA-directed CAR T product moved into earlier treatment after lenalidomide-refractory relapse.
What research teams should watch
Record refractory status and each prior drug class and plan referral before manufacturing and bridging timelines narrow the treatment window.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Relapsed or refractory multiple myelomaPRIMARY RECORDS